The Multidrug Resistance gene (MDR 1) is frequently expressed in acute myeloid leukaemia
(AML). MDR 1 is associated with resistance to chemotherapy in vitro and with a poor …

In order to confirm our initial report on the negative impact of MDR1 gene expression on the
outcome of de novo acute myeloid leukemia (AML), we present an update of our prospective …

The clinical significance of the multidrug resistance (MDR 1) gene phenotype was
investigated in newly diagnosed AML and was compared with other clinical and biological …

In an attempt to determine the incidence and clinical relevance of mdr1 gene expression in
acute myeloid leukemia (AML), we examined 126 specimens obtained from adult patients …

Introduction: The multidrug resistance protein 1 (MDR1) has the capacity to extrude
chemotherapeutics and has been implicated in treatment failure in acute myeloid leukemia …

Expression of the multidrug resistance (MDR1) phenotype, encoded by the MDR1 gene, is
an adverse prognostic factor for CR and survival in acute myeloid leukemia (AML). Other …

Resistance to multiple chemotherapeutic agents has been related to the production of P-
glycoprotein, a trans-membrane drug efflux pump that is encoded by the multidrug …

To prospectively assess the role of MDR1 gene expression in patients with de novo acute
myeloid leukemia (AML), levels of MDR1 RNA in blast cells were determined at diagnosis …

Resistance to cytotoxic agents may be encountered during the treatment of acute
myeloblastic leukaemia (AML). P-glycoprotein encoded by the MDR-1 gene has been …

The expression of the MDR1 gene was studied by Northern blot analysis in leukaemic cell
specimens obtained from 74 patients with acute myelogenous leukaemia (AML). No …